Copyright
©The Author(s) 2022.
World J Clin Oncol. Feb 24, 2022; 13(2): 147-158
Published online Feb 24, 2022. doi: 10.5306/wjco.v13.i2.147
Published online Feb 24, 2022. doi: 10.5306/wjco.v13.i2.147
Table 1 Clinicopathological characteristics
| Characteristics | Number of patients (%) |
| Total | 24 |
| Median age (range), yr | 58 (36-77) |
| Sex | |
| Male | 15 (62.5) |
| Female | 9 (37.5) |
| ECOG at TPEx treatment initiation | |
| 0-1 | 22 (91.7) |
| 2 | 2 (8.3) |
| Smoking history | |
| Never | 6 (25) |
| Current or former | 13 (54.2) |
| NS | 5 (20.8) |
| Alcohol consumption | |
| Occasional or regular | 8 (33.3) |
| None | 7 (29.2) |
| NS | 9 (37.5) |
| Primary tumor site | |
| Larynx | 7 (29.2) |
| Oropharynx | 6 (25) |
| Oral cavity | 5 (20.8) |
| Hypopharynx | 1 (4.2) |
| Other | 5 (20.8) |
| Previous treatment | |
| Concomitant chemoradiotherapy only | 8 (33.3) |
| Surgery only | 5 (20.8) |
| Surgery + concomitant chemoradiotherapy | 5 (20.8) |
| Surgery + radiotherapy | 3 (12.5) |
| Radiotherapy only | 1 (4.2) |
| No | 2 (8.3) |
| Extent of disease at TPEx treatment initiation | |
| Locoregional recurrence only | 14 (58.3) |
| Locoregional recurrence + distant metastasis | 5 (20.8) |
| Metastatic disease | 5 (20.8) |
| Time from initial diagnosis to recurrence(Median, IQR), mo | 16.2 (5.4-37.5) |
| Metastatic or unresectable disease at diagnosis | 11 (45.8) |
- Citation: Falco A, Leiva M, Blanco A, Cefarelli G, Rodriguez A, Melo J, Cayol F, Rizzo MM, Sola A, Rodríguez Montani H, Chacon M, Enrico D, Waisberg F. First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study. World J Clin Oncol 2022; 13(2): 147-158
- URL: https://www.wjgnet.com/2218-4333/full/v13/i2/147.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i2.147